Biotech

Biotech Stocks

Biotech StocksMost BioTech stocks seem to be in the red today. We suspect that the downtrends in the market today have quite a bit to do with the Federal Reserve’s 2 day meeting that ends tomorrow. Nonetheless, here’s what we saw from BioTech stocks today…

Fastest Growing BioTech Stocks Today

  1. Orexigen Therapeutics, Inc. (NASDAQ: OREX) – Orexigen Therapeutics, Inc. (NASDAQ: OREX) stocks gained 7.88% or $0.55 per share; closing the day off at $7.53 per share.
  2. ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) – ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) stocks gained 3.63% or $0.48 per share; closing the day off at $13.71 per share.
  3. Regeneron Pharmaceuticals Inc (NASDAQ: REGN) – Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stocks gained 3.55% or $16.03 per share; closing the day off at $467.80 per share.
  4. Inovio Pharmaceuticals Inc (NASDAQ: INO) – Inovio Pharmaceuticals Inc (NASDAQ: INO) stocks gained 1.66% or $0.14 per share; closing the day off at $8.56 per share.
  5. Celgene Corporation (NASDAQ: CELG) – Celgene Corporation (NASDAQ: CELG) stocks gained 0.16% or $0.19 per share; closing the day off at $121.03 per share.
  6. AMGEN INC (NASDAQ: AMGN) – AMGEN INC (NASDAQ: AMGN) stocks gained 0.02% or $0.04 per share; closing the day off at $163.07 per share.

Fastest Falling BioTech Stocks Today

  1. Amarin Corporation plc (ADR) (NASDAQ: AMRN) – Amarin Corporation plc (ADR) (NASDAQ: AMRN) stocks lost 16.84% or $0.48 per share; closing the day off at $2.37 per share.
  2. Biocept Inc (NASDAQ: BIOC) – Biocept Inc (NASDAQ: BIOC) stocks lost 5.91% or $0.15 per share; closing the day off at $2.39 per share.
  3. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) – Intercept Pharmaceuticals Inc (NASDAQ: ICPT) stocks lost 4.8% or $14.37 per share; closing the day off at $280.11 per share.
  4. Oncolytics Biotech Inc. (NASDAQ: ONCY) – Oncolytics Biotech Inc. (NASDAQ: ONCY) stocks lost 4.12% or $0.03 per share; closing the day off at $0.71 per share.
  5. Cytori Therapeutics Inc (NASDAQ: CYTX) – Cytori Therapeutics Inc (NASDAQ: CYTX) stocks lost 3.65% or $0.05 per share; closing the day off at $1.32 per share.
  6. Genetic Technologies Limited (ADR) (NASDAQ: GENE) – Genetic Technologies Limited (ADR) (NASDAQ: GENE) stocks lost 3.60% or $0.16 per share; closing the day off at $4.29 per share.
  7. AEterna Zentaris Inc. (NASDAQ: AEZS) – AEterna Zentaris Inc. (NASDAQ: AEZS) stocks lost 1.49% or $0.01 per share; closing the day off at $0.53 per share.
  8. MannKind Corporation (NASDAQ: MNKD) – MannKind Corporation (NASDAQ: MNKD) stocks lost 1.00% or $0.06 per share; closing the day off at $5.45 per share.
  9. Gilead Sciences Inc. (NASDAQ: GILD) – Gilead Sciences Inc. (NASDAQ: GILD) stocks lost 0.85% or $0.86 per share; closing the day off at $100.44 per share.

Know Of Any Other Fast Moving BioTech Stocks?

align=”center”>

Let us know in the comments below!

Image Credit

Amarin Stock News Today

Amarin Stock News TodayAmarin (NASDAQ: AMRN) is one of the most talked about stocks in the BioTech space today. After a top analyst upgraded the stock last week, it climbed astronomically in end of week trading. However, the story seems to be a bit different this week, and people are starting to wonder why. So, today we’ll briefly discuss the analyst upgrade that led to the incredible increase in the value of Amarin (NASDAQ: AMRN) stocks toward the end of last week, take a look at the declines we’ve seen so far this week, and discuss whether or not Amarin (NASDAQ: AMRN) is headed for long term growth.

HC Wainwright Upgrades Amarin (NASDAQ: AMRN) Stocks To Buy!

On Thursday, a well respected analyst from HC Wainwright upgraded Amarin (NASDAQ: AMRN) stocks from a “Neutral” rating to a “Buy” rating. Upon the upgrade, the analyst increased the stock’s target price to $10; showing that he expects to see exponential growth from the stock over the long term. As a result, the value of shares of Amarin (NASDAQ: AMRN) started to skyrocket; gaining more than 20% per day on both Thursday and Friday.

Amarin (NASDAQ: AMRN) Stocks Started To Decline This Week

Unfortunately, the momentum just couldn’t be maintained. As soon as markets opened Monday, Amarin (NASDAQ: AMRN) stocks started to fall. Unfortunately, that fall has continued into trading today. After starting the day off yesterday at well over $3.20 per share, the stock fell dramatically in morning trading with slow downtrends throughout the day. By the end of the day, Amarin (NASDAQ: AMRN) stocks fell to $2.85 per share.

Today, we’ve seen much of the same in the price of Amarin (NASDAQ: AMRN) stocks. Throughout morning trading, the stock continued the strong downtrends. However, around 11:20 (when the stock was trading at $2.31 per share), things started to pick up. While much of the loss has been recovered, it doesn’t look like the stock is going to make it to the green today. Currently (2:58), Amarin (NASDAQ: AMRN) is trading for $2.49 per share after a loss of 12.63% so far today.

Why Are Amarin (NASDAQ: AMRN) Stocks Falling?

While looking at more than 10% losses on the value of a share two days in a row can be a bit hard to take, the movement is actually pretty natural. It’s all the result of investor excitement. When good news comes out about an asset, investors tend to pump money into the asset, hoping to bank on gains. However, when the gains start to roll in, it’s not uncommon for investors to put more and more money into the stock as they become more and more excited about the money they’re making. As a result, we tend to see dramatic uptrends like we saw with Amarin (NASDAQ: AMRN) stocks last week.

However, fast paced upward growth generally doesn’t last forever. At some point, investors start to realize that the value of a stock is growing too fast, and pull out to protect their investments. This is when the correction happens. While upward growth is warranted with Amarin (NASDAQ: AMRN), 20% growth per day is a bit too much! So, the market seems to be correcting the unwarranted excessive growth. Again, this is completely healthy for the stock.

Where Will Amarin (NASDAQ: AMRN) Stocks Go Long Term

To be honest, I think we’ve seen the brunt of the drop. Amarin (NASDAQ: AMRN) stocks have started to make a recover in end of day trading today and will most likely continue that recovery throughout the week. The bottom line is that the company is a great stock, and I agree with the target price of $10…it’s just not healthy to go from here to there over the course of two weeks; and with trends like we saw last week, that’s what would have happened.

What Do You Think?

Do you think Amarin (NASDAQ: AMRN) stocks are a good long term investment choice? Let us know in the comments below!

Biotech Stock News Today

Biotech Stock News TodayAmarin (AMRN) Stocks Continue To Decline Following A Strong End Last Week

Last week, Amarin (AMRN) stocks nudged up incredibly fast as a top analyst upgraded the stock from a “Neutral” to a “Buy” rating; moving the target price to 10% and insinuating strong upward growth. However, it seems as though the excitement about the upgrade died over the weekend because the stock is down so far this week. Currently (12:10), the stock is trading at $2.48 per share, down 12.98% so far today.

Outlook – When the upgrade happened, there wasn’t much surprise. Remember, Amarin (AMRN) stocks just had another big kick in February when analysts at SunTrust bank upgraded the stock. With that being said, I think the downtrends we’re seeing are a classic case of too much too fast. Investors got excited and let their emotions send the stock climbing further than it should have Thursday and Friday. As a result, we’re seeing a bit of a correction this week. Nonetheless, the stock is still a great long term investment option!

Cytori (CYTX) Stocks Are Down After An Impressive Run

Following the Cytori (CYTX) earning report, we started to see a rally in the stock. While the report showed that there were losses in the fourth quarter and in the entire year of 2014, for some reason, investors were still excited. Nonetheless, the stock is trading in the red so far today.

Outlook – As I’ve mentioned in the past, when I invest, I’m in it for the long run. With that said, I tend to invest in companies that are already generating profits and have a proven track record of doing so quarter after quarter. Unfortunately, Cytori (CYTX) is a company that’s currently operating as a loss; which is a major red flag for me. While I’d love to see growth long term, I wouldn’t be confident enough in their ability to profit until they’ve proven that they can do so.

Inovio Pharmaceuticals (INO) Stocks Look To Be Continuing The Uptrend

Yesterday, we saw a great jump in the value of Inovio Pharmaceuticals (INO) stocks following the release of the company’s earnings report. While the company did generate a loss throughout the year, the company was able to show promise in growth. This morning, the momentum seemed to turn the other way in morning trading. However, after falling to the day’s low of $7.88 per share at 9:50, we started to see an incredible recovery. Currently (11:25), Inovio Pharmaceuticals (INO) stock is trading at $8.30 per share for a loss of 0.12% so far today. The stock is on a strong uptrend at the moment; so, it could end the day in the green.

Outlook – As mentioned above, I’m not an investor that likes to funnel money into companies that have not proven that they are capable of generating profits consistently. Unfortunately, Inovio Pharmaceuticals (INO) falls into that category. However, depending on your unique investment goals, it may be an option for you.

Gilead Sciences (GILD) Stocks Fall Even After An Analyst Upgrade From S&P 500

Big news came in today as the S&P 500 announced that Gilead Sciences (GILD) would be moving up from position #92 to position #90. Unfortunately, investors don’t seem to be paying attention to the positive as news of a policy shift threatens dollars has started to break. As a result, Gilead Sciences (GILD) stocks are down today; falling 1.20% so far (12:32) to $100.08 per share.

Outlook – While policy changes surrounding the BioTech space may be a bit of a concern to me, I’m pretty impressed with what Gilead Sciences (GILD) has accomplished. They’ve made waves in advancements of treatments of Hepatitis C and several other ailments; and will continue to do so. With that said, I see this one in the green for the long run.

Amgen (AMGN) Stocks Are Down Today Following Major Growth Yesterday

Yesterday, investors were all over Amgen (AMGN) stocks as the company announced data gathered from Repatha phases 2 and 3. The data was overwhelmingly positive news, showing that the company is reaching goals with advancements in the cardiovascular treatment. However, the movement in the company’s stock value today isn’t so positive. So far today (12:39), the stock has lost 0.49% and is currently trading at $162.23 per share.

Outlook – While Amgen (AMGN) stocks may be on the decline today, when it comes to earnings, this company is known for producing profits. With that said, I see great things in the future of Amgen (AMGN) stocks!

What Do You Think?

Do you have an opinion on any of the stocks mentioned here? We’d love to see it in the comments below!

Image Credit

Biotech stocks today

Biotech stocks todayAcadia Pharmaceuticals (ACAD)

Shares of Acadia Pharmaceuticals tanked around 30% in after hours trade on 3/11/15 after it had announced two different sets of news. The first set of news was that the CEO of Acadia Uli Hacksell would not only be stepping down as the CEO of the company but stepping down from the board of directors as well. Uli Hacksell has been the company CEO since 2000 so his departure now is a little bit awkward in nature. Why the CEO has decided to depart now is not clearly known, but this type of news never bodes well for the stock in the short-term as it creates a lot of uncertainty. For the time being the current Chief Financial Officer Steve Davis will take over as the Interim CEO until the company can find a more suitable person to run the company.

In addition to the CEO retiring abruptly Acadia reported that it would have to delay the NDA filing for Nuplazid — known as pimavanserin — all the way until the 2nd half of 2015. This puts the company way behind schedule because without this delay the company would have filed the NDA for Nuplazid this month in March. Typically when a company files for FDA approval for a drug it takes about 10 months or so for review by the FDA panel. Therefore this delay puts a huge roadblock for the company itself. If the company files for NDA approval by the 2nd half of 2015 that would put the FDA review time around mid 2016. Nuplazid is a selective serotonin inverse agonist that is being used to target 5-HT2A receptors in patients with Parkinson’s Disease Psychosis. More specifically the company is targeting the non-motor functions associated with the disease. That means the drug will be primarily targeting mental problems that patients would typically experience with Parkinson’s.

The one key thing to note though is that Nuplazid is a New Chemical Entity — NCE — which means that the FDA has never approved a drug of this chemical type. In addition the FDA provides companies that seek FDA approval for NCE drugs longer market exclusivity which gives the company longer access to sell the drug for greater revenue. Nuplazid was being tested in a large phase III trial that enrolled 199 patients in total in which patients were randomized. Each set of patients either received 40 mg of Nuplazid or a placebo compound once-daily for 6-weeks straight. Patients were then screened two weeks later to determine if Nuplazid showed greater efficacy than its placebo counterpart. The trial proved that Nuplazid was better than its placebo counterpart according to a sophisticated scale known as the SAPS-PD — Scale for the Assessment of Positive Symptoms. The Nuplazid arm demonstrated a 5.79 point improvement in psychosis at day 43 compared to placebo which only showed a 2.73 point improvement in the same time period. The difference of 3.06 points created a p-value of p =.001, which means the trial was significant and met the primary endpoint of the study. If ultimately approved Nuplazid would be the first drug ever to be approved for Parkinson’s Disease Psychosis — which deals with the non-motor part of the disease. Investors should keep an eye on this company in the coming months as it may soon recover despite these setbacks. More about the press release can be found here.

Neuralstem (CUR)

Shares of Neuralstem tanked around 30% on 3/12/15 after the company reported results for its phase II trial being pursued to treat patients with Amyotrophic lateral schlerosis. The company is using stem cell therapy in hopes of being able to regenerate the patient’s brain and spinal cord to improve movement functions. The primary endpoint of the study was set up to test safety. This was to determine if a patient could be transplanted with 16 million cells in a surgery format and that the patient would be able to tolerate such a treatment.

The Secondary endpoint of the study was to assess efficacy of Neuralstem’s drug NSI-566 in patients with ALS. There were about 7 out of 15 patients, or 47% who responded to the stem cell therapy treatment. One thing to take note of is that the company chose to run this trial as a stand-alone trial meaning there was no placebo counterpart involved. While there is no placebo to compare the company’s treatment to we can say that trial was still successful in that roughly 50% of the patients enrolled responded to the treatment. These patients with ALS have few treatment options that can help them so having about half of the patients respond to NSI-566 shows great promise. For instance the one treatment that does exist for ALS, known as Rilutek, has a lot of side effects. For example side effects from Rilutek that have a greater than 10% chance of occurring are: Nausea, Weakness, and decreased lung function. This compares to Neuralstem’s NSI-566 treatment with only one patient who experienced a surgical adverse event.

It is no question that the share price for Nueralstem has tanked on this news but it seems a lot of investors have misunderstood what these results were establishing. The company intentionally ran a phase II trial without a placebo counerpart. Contrary to popular belief biotech companies don’t do this because their drug is a failure. They do this to determine the maximum tolerated dose and to see what efficacy can be achieved with the current treatment regimen — consider it like an exploratory trial. Going forward the company can fine tune the primary endpoint of the trial with the FDA and in addition they can now run a larger trial with a placebo counterpart. Which means the company will be able to assess the NSI-566 treatment in terms of efficacy by comparing it to a placebo compound. Neuralstem expects this larger trial for NSI-566 to begin by the summer of 2015 although results from this trial won’t probably be ready until sometime in 2016. Going forward the company is in good shape therefore investors should look into the company’s pipeline prospects. Having said that there is still a lot of risk going forward both in short-term swings and long term volatility depending upon further trial results. More about this news can be found here.

Amarin Corporation PLC (AMRN)

Shares of Amarin have been on a huge upswing lately especially after the huge analyst upgrade which occurred on 3/12/15. The analyst upgrade came from HC. Wainwright which took Amarin from a Neutral to a Buy Rating with a price target of $10 per share. Shares of Amarin soared roughly 23% on that analyst upgrade and in addition went up the next day an additional 20%. Shares of Amarin are up 50% over the last 5 days and there is plenty of room for the share price to appreciate in the coming months.Amarin is responsible for producing a drug known as Vascepa which was approved by the FDA back in July of 2012 to reduce patients’ high triglyceride levels. The company has done well and continues to do well with Vascepa as it continues to grow its product revenue in the market. For instance product revenue for year-end 2014 was at $54.2 million dollars  compared to $26.4 million by year end 2013, which is a 105% increase year over year. The company is set in terms of funds for quite some time as well because in the week prior the company had announced that it had entered into a private placement agreement with both current and new investors for approximately $52 million dollars in funding. The company will use these funds for general corporate purposes and in addition continue to market its cholesterol drug Vascepa in multiple territories.

Image Credit

Biggest Moving Stocks Today

Biggest Moving Stocks TodayAs always, today was an exciting day in the market. Here’s a list of the top moving stocks by industry today…

Tech’s Biggest Moving Stocks

Tech’s Fastest Growing Stocks Today

  • Apple (AAPL) – Apple stocks closed the day off at $124.25 per share after a gain of $1.36 or 1.10%.
  • MicroVision (MVIS) – MicroVision stocks climbed to $3.14 per share today after a gain of $0.40 per share or 14.60%.
  • Neonode (NEON) – Neonode stocks climbed to $2.82 per share today after a gain of $0.12 per share or 4.44%
  • Vringo (VRNG) – Stocks gained $0.02 per share or 2.27% today; closing the day at $0.79 per share.
  • NQ Mobile (NQ) – NQ Mobile stocks gained $0.28 per share or 7.89% today; closing the day off at $3.83 per share.

Tech’s Fastest Falling Stocks Today

  • Plug Power (PLUG) – Plug Power stocks closed the day at $2.75 per share after losing $0.11 or 3.85%
  • BlackBerry (BBRY) – BlackBerry stocks closed the day $0.09 per share in the red after losing 0.92%. The stock closed the day at $9.72 per share.
  • Himax Technologies (HIMX) – Himax Technologies stocks closed the day at $7.47 per share after losing $0.51 or 6.39%.
  • Twitter (TWTR) – Twitter saw a loss today closing at $46.43 per share after losing $0.23 or 0.49%.
  • Zynga (ZNGA) – Zynga lost $0.02 per share or 0.77% in trading today; closing the day off at $2.57 per share.

BioTech’s Biggest Moving Stocks

BioTech’s Fastest Growing Stocks Today

  • Inovio Pharmaceuticals (INO) – Inovio Pharmaceuticals stocks gained $1.38 per share or 19.60% today; closing the day at $8.42 per share.
  • Cytori (CYTX) – Cytori stocks climbed $0.17 per share or 14.17% today; closing the day off at $1.37 per share.
  • Gilead Sciences (GILD) – Gilead Sciences stocks climbed $1.69 per share or 1.70% today; closing the day off at $101.30 per share.
  • Ariad Pharmaceuticals (ARIA) – Ariad Pharmaceuticals saw a gain of $0.22 per share or 2.60% today; closing the day off at $8.70 per share.
  • Regeneron Pharmaceuticals (REGN) – Regeneron Pharmaceuticals stocks gained $22.39 per share or 5.21% today; closing the day off at $22.39 per share.
  • Amgen (AMGN) – Amgen stocks climbed $8.77 per share or 5.69% today; closing the day off at $163.03 per share.

BioTech’s Fastest Falling Stocks Today

  • Amarin (AMRN) – Amarin stocks lost $0.05 per share or 1.72% today; closing the day off at $2.85 per share.
  • Genetic Technologies (GENE) – Genetic Technologies stocks lost $0.26 per share or 5.52% today; closing the day off at $4.45 per share.
  • BG Medicine (BGMD) – BG Medicine stocks lost $0.01 per share or 1.16% today; closing the day off at $0.85 per share.
  • Biocept (BIOC) – Biocept stocks lost $0.28 per share or 9.93% today; closing the day off at $2.54 per share.

Know Of Any Others?

Let us know in the comments below.

Image Credit

BioTech Stocks To Watch Today

BioTech Stocks To Watch TodayCytori (CYTX) Stocks Continue To Climb Following Poor Earnings

I’ve always found it interesting when a company produces a poor earnings report, but their stocks react in a positive way. For instance, look at Amazon for the life of its performance in the stock market! Nonetheless, Cytori (CYTX) seems to be capable of doing just that. After producing a report that showed a loss of $0.08 per share, the stock fell 9% before making a dramatic recovery to close the day Friday in the green. The end of day upward momentum we saw Friday seems to be carrying through to today. Currently (1:03) the Cytori (CYTX) stocks are trading for $1.33 after gaining 10.82% so far today!

Outlook – While I’m not personally willing to join the frenzy with the company producing a loss, it’s obvious that the stock gained a bit of momentum; which will most likely carry through at least the rest of the day.

Inovio Pharmaceuticals (INO) Stocks Soar On Slightly Positive Earnings Report

Here’s another company that despite producing losses, is soaring in the stock market today. Inovio Pharmaceuticals (INO) recently provided their Q4 and year end earnings report; and I didn’t find much positive about it. In the quarter, the company produced a loss of more than $7 million. While the loss is much less than the loss the company took the year before, it’s still a loss; and in my humble opinion, losses are bad. Nonetheless, the company’s stock is climbing dramatically. After a gain of 18.18% so far today (1:10), the stock is trading at $8.32 per share.

Outlook – This is another one where the upward momentum is definitely exciting, but I think I’d resist the urge to buy. As an investor, I’m most excited when a company shows high potential for long term growth. The bottom line is that a company cannot survive on losses for very long (a few years, maybe, but not much longer than that). Therefore, until Inovio Pharmaceuticals (INO) starts to produce profits, I’d personally stay away.

Genetic Technologies (GENE) Stocks Aren’t Sure Where To Go

After struggling through share dilution last week as a result of successful fund raising, investors in Genetic Technologies (GENE) are hoping for a recovery this week. However, it seems as though the stock price is confused as to where to go. This is most likely the result of investors waiting to make sure that downtrends are over and growth can start again. Nonetheless, the stock is currently (1:16) trading at $4.50 per share after losing 4.46% so far today through a series of dramatic ups and downs.

Outlook – Call me an optimist, but I still think that Genetic Technologies (GENE) is going to end the week in the green. I think the effects of share dilution are over and it’s time for investors to start feeling comfortable with the stock again this week.

Regeneron Pharmaceuticals (REGN) Stock Is Showing Impressive Growth

So far today, Regeneron Pharmaceuticals (REGN) is showing incredibly impressive growth; currently trading in all-time high territory. Following an incredible month, I think what we’re seeing here is the beginning of a relatively long-term uptrend! Currently (1:22) the company’s stock is trading at $446.92 per share after gaining 4.08% so far today.

Outlook – This one is obvious. Regeneron Pharmaceuticals (REGN) stocks have been soaring in value recently and are show.

MannKind (MNKD) Continues To Struggle To Gain Momentum

This one is very upsetting. MannKind (MNKD) is a great company, with great new products that wasn’t given a fair shake in the most recent analysis of the stock by Goldman Sachs. As a result, Goldman Sachs downgraded the company’s stock in a move that has been viewed as controversial to say the least. While I’m expecting to see somewhat of a recovery throughout the week, the stock is down so far today. Currently (1:26), MannKind (MNKD) stocks are trading at $5.47 per share after falling 0.73% so far today.

Oultook – As mentioned above, MannKind (MNKD) is a great company with great products, and in my opinion, it’s slated for growth. Although the stock does seem to be a bit confused today, I think we’re going to see positive movement overall today as more and more investors start to forget the unfounded Goldman Sachs downgrade.

What Do You Think?

Where do you think the stocks mentioned here are headed? Let us know in the comments below!

Image Credit

Amarin AMRN stock news

Amarin AMRN stock newsAmarin (AMRN) stocks have shown some pretty impressive growth last week; climbing more than 20% per day on both Thursday and Friday brought the stock to a strong close for the week. The dramatic uptrend leads to a big question among investors who have already bought into the trend, or are considering buying a few shares of their own. Will the positive trend continue or is the stock destined to fall back down? In my personal opinion, I’m going to go with the continuation of the positive trend. Here’s why…

Amarin (AMRN) Stocks Have Already Been Trending Up For Some Time

While Thursday and Friday we saw an explosion in the stock price, we can’t discount the fact that Amarin (AMRN) stocks were already growing in value before the pace picked up on Thursday. As a matter of fact, on Wednesday (the day before the big trend), the stock was up to $1.94 per share from $1.01 per share just 3 months before. So, regardless of the analyst upgrade and the dramatic uptrend it caused, Amarin (AMRN) stocks were already headed in the right direction. The new developments just helped them get there faster.

The Analyst Upgrade That Led To The Trend In The First Place

If you follow the trend back to the beginning of the day Thursday, it’s easy to find the cause. A well respected analyst at a firm named HC Wainwright upgraded the stock from a “Neutral” rating to a “Buy” rating and setting the target price for Amarin (AMRN) at $10. This was a very big move. Not only was the analyst that researched data for the upgrade incredibly experienced and well respected, he set the target price for the stock to a range that no one expected. With a target price at $10 per share on a stock that was trading at under $2 insinuates that the analyst believes in massive potential for upward growth in the stock with very little downward risk.

Amarin (AMRN) Is A Great Company With In Demand Products

Another thing I look into when thinking about whether or not a stock will grow over the long run is the company’s proven ability, or lack there of, to continue expanding its offering and make strides toward betterment. That’s exactly what Amarin (AMRN) has proven to do! It’s clear that Amarin (AMRN) is great at producing and marketing new medications. Their desire to continue to better the company is something that I don’t see slowing to a halt anytime soon.

What Do You Think?

Do you think Amarin (AMRN) stocks are on a long term uptrend or will we start to see downward movement soon? Let us know in the comments below!

Image Credit

US Equities News

US Equities NewsHalfway through March, S&P500 is flat on the year and in the middle of its upper/lower ranges winter home.  A range that is running into a 5th consecutive month. Hey, winter feels longer to Bostonians, so quit the complaining!.

Seems the consensus sell side positive return for the S&P in ’15 might be a little behind the curve by the time Q1 wraps up in a few weeks. Europe continues to dominate (as it should ) w/ negative interest rate policy running in tandem with QE kick off last week and cheap Oil.  A WAYS TO GO!   YPT never got excited over the oil swoon as a U.S growth catalyst short term, even if YPT view was “6 months of pain ahead”, following OPEC on November 27th. OPEC 27/11.  Instead the premise here was it eventually was going to be a ‘wash’ ST with U.S dollar strength. This wash premise is taking on a whole new flavour with USD recent surge. Earnings are now facing a greater headwind, back-end January Q1 guidance is likely out the window for the multinationals a month and a half later. EARNINGS DRAG

This lacklustre S&P performance in 2015 is really not a concern here, our DAX Europe trade is +20% but most importantly, YPT had a great Q1 with our SMID growth niche stock picks giving us a plethora of large % gainers. This gives us the luxury of sitting quietly into the back end of the Q as the broad market falls off highs and confuses itself with BAD news is GOOD news and vice versa off the deluge of daily global moving parts. (Eco’#’s, USD, IR dates, EUROZONE QE, NIRP etc). 

All the noise can be overwhelming, if trying to decide what to do with your money and/or how to invest it. (If you’re in Europe, negative rates on your money is not going too far. Eventually after most options are used up, equities will begin to get their fair share). In U.S equities, YPT prefers to wait it out as another Q of EPS is not far away. Earnings season is 4X a year and with corporations spreading out reports more than in the past it seems, this EPS niche gig is almost 12 months a year now!. At this point, SMIDs are outperforming due to greater domestic exposure and we’re seeing this creep into the major indexes as big and small diverge some last week. Impact of IR hikes on small caps is not playing a role yet as the USD roll takes precedent. In this view there is no reason, we can’t have another strong Q2 in our SMID niche at this point. 

We’ll get some light on USD impact as FEB- END Q reports trickle in next week. (ADBE ORCL in tech, NKE). Of course, the highlight this week is the FOMC. We already noted post big rally on Thursday, a sell the move should be in the cards pre-FOMC. It didn’t even wait for Monday, it sold off Friday. Despite the soft retail late last week, bad news is not taking the June Hike off the table despite the market attempts to make bad into good!. The fact this phenomenon and its gains were erased within 24hrs, makes it likely this trade is running thin. The scrap of ‘Patient’ to the FOMC word heap is seemingly inevitable, so there is more in the statement that will be used to deduce what it all means. In all, please erase the word, so markets can get on with it!. We’ll cover ole’ Yeller’s possible statement in more detail with YPT morning calls come Tuesday/ Wednesday. 

All in, its not like we are just taking this cautious stance in mid March, YPT highlighted everything wrong with the market going higher at the end of February at its highs and said a revisit to the months long range would be soon. (In ITTW 02.03.15 and almost on a daily basis since).

Still, oppy’s are present in YPY Shadow plays with QNET relative out performance, particularly with a handful of last Q EPS winners hovering near highs. Despite a ~2+% decline in the week, QNET sits the same number in the black for the year.  Still as QNET jousts with support in the latter part of week, the herd is starting to exhibit over zealousness in IWM/Nasdaq outperforming vs. SP/DJIA last week. This is not new news to YPT via our QNET gauge recently, but it seems to have garnered social media attention this weekend.

In all, view/a sense is this market is one valuation day puke from a visit to the lower 4 month S&P band. One day will likely become two as the market has not had a MOMO dump in awhile, including little participation in the 2 sell offs last week. The complacency and over confidence in IWM/Nasdaq exhibited end of week may just be the ticket to provoke such a move. Something like one of the last shoes to drop as many markets get obliterated in March.

Onto YPT Shadowlist Plays ~70… <YPTPremium> members only..To receive ‘INTO THE TRADING DAY’, 5 times a week before 8:30 am, follow the link: YPT PREMIUM

GOOD TRADING!

www.YourPersonalTrader.com

Image Credit

Stocks To Watch This Week

Stocks To Watch This WeekWill Apple (AAPL) Stocks Make A Recovery This Week?

While Apple (AAPL) is the largest company in the world, their business isn’t immune to mistakes. After a botched Spring Forward event last Monday, Apple (AAPL) stocks started to decline. Throughout the week, there were ups and downs as always; but for the most part, what we saw was downtrends. Throughout the week, Apple (AAPL) stocks lost around $5 per share and investors are hoping for a recovery this week. Will the recovery happen?

Outlook – Apple (AAPL) is a great company that in my opinion will definitely grow over the long run. However, I don’t think this is going to be a big week for the stock. With a bad taste already in the mouths of investors following Spring Forward and the poor performance last week, and concerns revolving the Federal Reserve’s current low interest rates taking center stage this week, I think Apple (AAPL) stocks will be in the red yet again. However, as I mentioned above, I do believe that Apple (AAPL) is a great company and their stocks are a great option for long term growth. With that said, this week may present a great buying opportunity.

Facebook (FB) Stocks Could Get A Good Push This Week

Facebook (FB) has definitely grown in popularity among investors and in value over the last few months. Following the news that the company has extended it’s advertising customer base greatly, and the recent positive Q4 earnings report, Facebook (FB) stocks have done incredibly well. However, the stock did end the week on the down beat along with most other tech stocks last week as fears continue to mount about what will come of the Federal Reserves mid-week meeting this week.

Outlook – While I’m not expecting to see massive growth from Facebook (FB) stocks this week, I am expecting to see slow growth, with the stock most likely ending the week in the green. While anticipation of the Federal Reserve’s statement will most likely be a drag on the market this week, Facebook (FB) is proving to be a company that’s growing in strength. With major concerns revolving the largest company in tech, Apple (AAPL), investors will most likely see Facebook (FB) as the more appealing choice at the given moment. So, the increased demand should offset the losses as a result of interest rate hike fears.

Will Zynga (ZNGA) Stocks Continue Rising On “Dawn of Titans”?

Following turbulent times in the market, Zynga (ZNGA) stocks have had a very strong month. Last week, the growth continued as the company released the latest game expected to be a smash hit, “Dawn of Titans”. While the stock did dip a bit toward the end of the week along with most of the tech space, overall, it seems as though investors are happy with what they’re seeing from the company as of late. The big question now is…Will the upward momentum continue?

Outlook – While Zynga (ZNGA) has struggled to gain momentum in recent months, they’ve shown over the past month that the company is getting back on track. At this point, I’m starting to regain my faith. While I’m still not 100% convinced that this is a good long-term option, I will be watching closely and expect that to change relatively soon.

BlackBerry (BBRY) Stocks Should Recover This Week

Last week, investors were taken by surprise when Goldman Sachs decided to downgrade BlackBerry (BBRY) stocks to a “Sell” rating. Upon quite a bit of research, the downgrade became even more interesting to me as I believe it was completely unfounded. Nonetheless, as we would generally expect, investors reacted to the downgrading with a swift sell off. As a result, BlackBerry (BBRY) stocks fell throughout the week. However, I think this week is going to be a completely different story.

Outlook – As I mentioned several times last week, BlackBerry (BBRY) is a great company and in my opinion, a great investment opportunity. In the middle of last week, we started to see a bit of a recovery, however, concerns over the Federal Reserve’s plans with regard to interest rates drug the stock down Friday with the rest of tech. While the anticipation and result of the Federal Reserve’s official statement is expected to be a drag on growth, I still think BlackBerry (BBRY) will end the week in the green as investors start to realize the tremendous buying opportunity the low cost stocks have become.

Plug Power (PLUG) Stocks Should Get Good Traction From Today’s Earnings Report

Plug Power (PLUG) stocks have had a bit of a rough time lately. However, I’m expecting that to change. Tomorrow, the company will be releasing their Q4 earnings report; and if it’s anything like analysts expect it to be, we’re going to see gains. Last week, the stock ended confused as to where to go, but with expectations for a strong earnings report, this week is slated to be great!

Outlook – As I mentioned above, experts are expecting to see great things from Plug Power (PLUG) in today’s earnings report. Because positive earnings generally cause positive momentum in the market, I’m expecting to see this one in the green throughout the week.

Will Amarin (AMRN) Stocks Continue Upward Trends This Week?

Last week proved to be an incredibly strong week for Amarin (AMRN) stocks. Following another upgrade of the stock from a well respected analyst, the stock gained more than 20% in value on both Thursday and Friday. Now, the question is whether or not the stock will continue the strong upward momentum or not.

Outlook – I don’t think the question here is whether or not the upward momentum will continue. After all, it would take very bad news to knock Amarin (AMRN) stocks off the pedestal they are currently on. In my opinion, the real question is “Will the inevitable growth continue at such a fast rate?”. I’ll keep you posted on the answer as we start to see movement.

 

It’s Time For A MannKind (MNKD) Stock Recovery

MannKind (MNKD) stocks have had a rough time in the market lately. Following a controversial downgrade from Goldman Sachs, the company’s stock has fallen dramatically recently. However, after researching the downgrade, this one seems to be unfounded as well. The downgrade was based on the launch of a diabetes drug that had very little time on the market before the analyst formed the poor opinion. Nonetheless, the new drug, Afrezza, has proven to be a miracle to those who have tried it so far; so there’s no question in my mind that the medication will gain traction. Outlook – In my opinion, MannKind (MNKD) is a stock that has strong potential for upward growth and very little potential for losses. The reality is that investors are starting to realize that the downgrade was founded on poor data, and that what MannKind (MNKD) has in Afrezza is truly valuable. With that said, I’m expecting to see a bit of a comeback this week. While we may not see massive growth, I would expect to see MannKind (MNKD) stocks end the week in the green.

Genetic Technologies (GENE) Stocks Should Grow As Dilution Concerns Die Down

Recently, Genetic Technologies (GENE) stock took a major hit in the market as share dilution due to fund raising took its toll on the stock. Nonetheless, the end of the week was relatively positive for Genetic Technologies (GENE) stocks; but, will dilution continue to take a toll on the stock this week? Outlook – I think the drop in value we’ve seen due to share dilution is over at this point. From here, the stock has the ability to grown on its own merit once again; and I think that’s exactly what we’ll see.

Regeneron Pharmaceuticals (REGN) Stock Is Expected To Continue Climbing

Regeneron Pharmaceuticals (REGN) stocks have had a great time in the market over the past month, with impressive growth continuing through Friday. As a matter of fact, on Friday the company’s stock grew by $4.22 per share or 0.99%. Will we continue to see growth this week? Outlook – This is another one that I think we’ll see in the green throughout the week. While price volatility is a bit of a concern, through the peaks and valleys, we’re seeing uptrends on the horizons!

Will Acadia (ACAD) Stocks Recover?

Acadia (ACAD) investors were taken by surprise last week as the CEO of the company suddenly retired and the company delayed its new drug application with the FDA for its Parkinson’s disease treatment. As a result, the company’s stock plummeted toward the end of the week, ending the week off at $34.45 per share. Outlook – While it looks like the brunt of the decline has come to an end, I’m still a bit concerned about the direction of the company. There still hasn’t been any news revolving around the reason for the CEO’s sudden retirement, and I’m not too accepting of the “readiness” excuse for the NDA display. With that said, I don’t think we’re going to see much positive movement this week. What Do You Think?

Do you have an opinion on any of the stocks mentioned here? We’d love to see it in the comments below!

Image Credit

Cytori Stock News

Cytori Stock NewsYesterday, Cytori (CYTX) released their earnings report for the fourth quarter as well as the entire year of 2014. Unfortunately, the news wasn’t as good as investors would have liked. As a result, the company’s stock price fell hard in morning trading today; losing more than 9%. However, the momentum has changed direction and Cytori (CYTX) is back in the green. So, today we’ll talk about what we saw with regard to earnings, how investors reacted to the earnings report, and what seams to be the reason for Cytori (CYTX) stocks being back on the rise.

Cytori (CYTX) Earnings Report Was Far Less Than Impressive

Unfortunately, the Cytori (CYTX) earnings report showed that the company didn’t produce earnings at all; instead, the report was all about losses. Here are the main highlights from the report….

Quarterly Financials

  • Earnings Per Share – In the fourth quarter, Cytori (CYTX) produced a loss of $0.08 per share.
  • Q4 Revenue – In the fourth quarter, Cytori (CYTX) generated $2.47 million in total revenue.
  • Operating Cash – In the fourth quarter, the company’s operating cash decreased to $4.9 million.

Whole Year Financials

  • Full Year Revenue – In the year of 2014, Cytori (CYTX) generated $5 million in total revenue.
  • Full Year Contract Revenue – In the year 2014, Cytori generated $2.6 million via contract revenue (half of which was generated in Q4).
  • Full Year Loss – $38.5 Million was the total loss over the course of the year 2014; equating to $0.48 per share.

How Investors Reacted To The Earnings Report

As you could imagine from the information shared above, investors were less than happy with the report both on a quarterly level and on an annual level. Following the poor report, the stock fell by more than 9%. However, it seems as though investors are starting to look past the losses as the stock is showing an impressive end of day recovery. After falling more than 9% from yesterday’s previous close, the stock is now in the green; with growth above 6% from yesterday’s close.

Why Are Cytori (CYTX) Stocks Climbing In Value?

One thing that we have to keep in mind is that while the overall earnings report wasn’t great, all of the information wasn’t bad. For instance, over the course of the entire year of 2014, the company generated $2.6 million via contracted revenue. However, $1.3 million of the entire year’s total was generated in the fourth quarter; insinuating strong upward growth.

Another big development that happened yesterday that investors seem to have pushed to the side was the fact that Cytori (CYTX) regained it’s NASDAQ listing compliance status with regard to the stock’s market value.

What We Can Expect Moving Forward

When it comes to Cytori (CYTX), I can see the stock rising, however repeat losses are a major concern for me. While I wouldn’t buy until I see sustained growth, this is definitely one to watch closely. While I do have a strong feeling that the value of the stock will most likely grow; I’m still not 100% confident.

What Do You Think?

Do you think Cytori (CYTX) stocks will rise or fall in value in the long run? Why? Let us know in the comments below!

Image Credit

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 3784
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...